Wu ZY, et al. - In this retrospective analysis, researchers determined the efficacy and safety of surgery in combination with postoperative ¹²⁵I seed brachytherapy to treat the parotid gland's primary mucoepidermoid carcinoma (MEC). The study sample consisted of 108 patients with MEC treated with surgery plus postoperative ¹²⁵I seed brachytherapy between 2004 and 2016. Data reported that the 5- and 10-year overall survival were 98.8% and 95.8%, respectively. Poor prognostic factors were age ≥ 60 years and T4 disease. There were minor toxicities associated with acute radiation. Overall, the authors concluded that surgery plus ¹²⁵I seed brachytherapy seems to be an effective treatment for MEC parotid gland, capable with few complications of delivering satisfactory results.